Literature DB >> 11200871

Albuminuria and the renin-angiotensin system gene polymorphisms in type-2-diabetic and in normoglycemic hypertensive Chinese.

G N Thomas1, J A Critchley, B Tomlinson, Z S Lee, R P Young, C S Cockran, J C Chan.   

Abstract

BACKGROUND: Albuminuria predicts nephropathy-related mortality in Caucasian and Chinese populations. The involvement of renin-angiotensin system (RAS) gene polymorphisms in the pathogenesis of nephropathy has been described predominantly in Caucasian populations. We have previously suggested that the angiotensinogen 235T variant may be associated with nephropathy in diabetic Chinese. PATIENTS AND METHODS: To validate these findings and extend them to include non-diabetic nephropathy, we examined the association of albuminuria and gene polymorphisms of the angiotensinogen M235T, angiotensin-converting enzyme insertion/deletion and angiotensin II type I receptor A1166C polymorphisms in 614 Chinese subjects (66% type 2 diabetic, 16% normoglycemic hypertensives and 18% controls).
RESULTS: Obesity and higher blood pressure were associated with albuminuria in both diabetes and normoglycemic hypertension. In the diabetic group, albuminuria was also associated with increased insulin resistance and glycemic indices, duration of diabetes and adverse lipid profiles. Only the ACE gene polymorphism showed evidence of association with albuminuria, with the D allele being less frequent in the normoglycemic hypertensive patients with albuminuria (25.0%) than the controls (41.4%) or normoalbuminuric group (39.6%) and in those hypertensives at increased risk (albumin-to-creatinine ratio > 5.6 mg/mmol) of end-stage renal disease than those at lower risk (all p < 0.05), but not in the diabetic group. The D allele was also less prevalent in the total (31.9%) and normoalbuminuric (32.2%) diabetic groups than in the controls (p < 0.05).
CONCLUSION: In this cohort of Chinese subjects, the ACE gene polymorphism D allele was less frequent in normoglycemic hypertensive patients with albuminuria and in type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11200871

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  6 in total

1.  Albuminuria is a marker of increasing intracranial and extracranial vascular involvement in Type 2 diabetic Chinese patients.

Authors:  G N Thomas; J W Lin; W W M Lam; B Tomlinson; V Yeung; J C N Chan; K S Wong
Journal:  Diabetologia       Date:  2004-08-25       Impact factor: 10.122

2.  Sex differences in epidemiology and risk factors of acute coronary syndrome in Chinese patients with type 2 diabetes: a long-term prospective cohort study.

Authors:  Jian Gang Duan; Xiang Yan Chen; Li Wang; Alex Lau; Adrian Wong; G Neil Thomas; Brian Tomlinson; Roxanna Liu; Juliana C N Chan; Thomas W Leung; Vincent Mok; Ka Sing Wong
Journal:  PLoS One       Date:  2015-04-01       Impact factor: 3.240

Review 3.  A systematic review of the role of renin angiotensin aldosterone system genes in diabetes mellitus, diabetic retinopathy and diabetic neuropathy.

Authors:  Zohreh Rahimi; Mahmoudreza Moradi; Hamid Nasri
Journal:  J Res Med Sci       Date:  2014-11       Impact factor: 1.852

4.  Angiotensin II receptor type 1 A1166C modifies the association between angiotensinogen M235T and chronic kidney disease.

Authors:  Sui-Lung Su; Wei-Teing Chen; Po-Jen Hsiao; Kuo-Cheng Lu; Yuh-Feng Lin; Chin Lin; Wen Su; Shih-Jen Yeh; Hung Chang; Fu-Huang Lin
Journal:  Oncotarget       Date:  2017-10-26

5.  Long-term risk of cardiovascular disease among type 2 diabetic patients with asymptomatic intracranial atherosclerosis: a prospective cohort study.

Authors:  Jian Gang Duan; Xiang Yan Chen; Alex Lau; Adrian Wong; G Neil Thomas; Brian Tomlinson; Roxanna Liu; Juliana C N Chan; Thomas W Leung; Vincent Mok; Ka Sing Wong
Journal:  PLoS One       Date:  2014-09-05       Impact factor: 3.240

6.  Association between angiotensin II receptor type 1 A1166C polymorphism and chronic kidney disease.

Authors:  Hsiang-Cheng Chen; Sui-Lung Su; Hsien-Feng Chang; Po-Jen Hsiao; Yu-Juei Hsu; Fu-Huang Lin; Chin Lin; Wen Su
Journal:  Oncotarget       Date:  2018-02-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.